-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $45

Benzinga·01/08/2026 17:02:41
Listen to the news
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $48 to $45.